drugset
drugset / Trial / NCT01427946

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

NCT01427946 ↗

Phase 1/2 Completed 47 enrolled Infinity Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Study IPI-504-15 is a Phase 1b/2 clinical trial to evaluate the safety and efficacy of retaspimycin HCl (IPI-504) plus everolimus in patients with KRAS mutant Non-small Cell Lung Cancer (NSCLC).

Timeline

Start
2011-07
Primary completion
2014-06
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule — —
Subject retaspimycin Small molecule — —

Indications

non-small cell lung carcinoma